The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis

Marco Carbone, Stephen J. Sharp, Steve Flack, Dimitrios Paximadas, Kelly Spiess, Carolyn Adgey, Laura Griffiths, Reyna Lim, Paul Trembling, Kate Williamson, Nick J. Wareham, Mark Aldersley, Andrew Bathgate, Andrew K. Burroughs, Michael A. Heneghan, James M. Neuberger, Douglas Thorburn, Gideon M. Hirschfield, Heather J. Cordell, Graeme J. Alexander, David E.J. Jones, Richard N. Sandford, George F.

Aspartate aminotransferase to platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated pediatric cystic fibrosis liver disease

Daniel H. Leung, Mahjabeen Khan, Charles G. Minard, Danielle Guffey, Louise E. Ramm, Andrew D. Clouston, Gregory Miller, Peter J. Lewindon, Ross W. Shepherd, Grant A. Ramm – 29 July 2015 – Up to 10% of cystic fibrosis (CF) children develop cirrhosis by the first decade. We evaluated the utility of two simple biomarkers, aspartate aminotransferase to platelet ratio index (APRI) and FIB‐4, in predicting degree of fibrosis in pediatric CF liver disease (CFLD) validated by liver biopsy.

A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses

Eloi R. Verrier, Che C. Colpitts, Charlotte Bach, Laura Heydmann, Amélie Weiss, Mickaël Renaud, Sarah C. Durand, François Habersetzer, David Durantel, Georges Abou‐Jaoudé, Maria M. López Ledesma, Daniel J. Felmlee, Magali Soumillon, Tom Croonenborghs, Nathalie Pochet, Michael Nassal, Catherine Schuster, Laurent Brino, Camille Sureau, Mirjam B. Zeisel, Thomas F. Baumert – 29 July 2015 – Chronic hepatitis B and D infections are major causes of liver disease and hepatocellular carcinoma worldwide. Efficient therapeutic approaches for cure are absent.

A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses

Eloi R. Verrier, Che C. Colpitts, Charlotte Bach, Laura Heydmann, Amélie Weiss, Mickaël Renaud, Sarah C. Durand, François Habersetzer, David Durantel, Georges Abou‐Jaoudé, Maria M. López Ledesma, Daniel J. Felmlee, Magali Soumillon, Tom Croonenborghs, Nathalie Pochet, Michael Nassal, Catherine Schuster, Laurent Brino, Camille Sureau, Mirjam B. Zeisel, Thomas F. Baumert – 29 July 2015 – Chronic hepatitis B and D infections are major causes of liver disease and hepatocellular carcinoma worldwide. Efficient therapeutic approaches for cure are absent.

Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers

Peter Bannas, Harald Kramer, Diego Hernando, Rashmi Agni, Ashley M. Cunningham, Rakesh Mandal, Utaroh Motosugi, Samir D. Sharma, Alejandro Munoz del Rio, Luis Fernandez, Scott B. Reeder – 29 July 2015 – Emerging magnetic resonance imaging (MRI) biomarkers of hepatic steatosis have demonstrated tremendous promise for accurate quantification of hepatic triglyceride concentration. These methods quantify the proton density fat‐fraction (PDFF), which reflects the concentration of triglycerides in tissue.

Impact of the serum ferritin concentration in liver transplantation

Taiichi Wakiya, Yukihiro Sanada, Taizen Urahashi, Yoshiyuki Ihara, Naoya Yamada, Noriki Okada, Yuta Hirata, Kenichi Hakamada, Yoshikazu Yasuda, Koichi Mizuta – 29 July 2015 – The serum ferritin (SF) concentration is a widely available and objective laboratory parameter. SF is also widely recognized as an acute‐phase reactant. The purpose of the present study was to identify the chronological changes in the recipient's SF concentration during liver transplantation (LT) and to clarify factors having an effect on the recipient's intraoperative SF level.

Subscribe to